BACKGROUND/AIMS: Mild cognitive impairment (MCI) is frequent in Parkinson's disease (PD) and idiopathic REM sleep behavior disorder (iRBD). However, only a few studies have evaluated the validity of brief cognitive measures to detect MCI in PD or iRBD using standard diagnostic criteria for MCI. Our aim was to evaluate the validity of the Mini-Mental State Examination (MMSE) and the Mattis Dementia Rating Scale (DRS-2) to detect MCI in PD and iRBD. METHODS: Forty PD patients and 34 iRBD patients were studied. Receiver operating characteristic curves were created for both tests to assess their effectiveness in identifying MCI in PD and iRBD. RESULTS: In PD, a normality cutoff of 138 on the DRS-2 yielded the best balance between sensitivity (72%) and specificity (86%) with a correct classification of 80%. In iRBD, the optimal normality cutoff was 141 on the DRS-2, with a sensitivity of 90%, a specificity of 71% and a correct classification of 82%. No cutoff for the MMSE was found to have acceptable sensitivity or specificity. CONCLUSION: The DRS-2 has satisfactory validity to detect MCI in PD or iRBD. The MMSE proved to be invalid as a screening test for MCI in both populations.
BACKGROUND/AIMS: Mild cognitive impairment (MCI) is frequent in Parkinson's disease (PD) and idiopathic REM sleep behavior disorder (iRBD). However, only a few studies have evaluated the validity of brief cognitive measures to detect MCI in PD or iRBD using standard diagnostic criteria for MCI. Our aim was to evaluate the validity of the Mini-Mental State Examination (MMSE) and the Mattis Dementia Rating Scale (DRS-2) to detect MCI in PD and iRBD. METHODS: Forty PDpatients and 34 iRBD patients were studied. Receiver operating characteristic curves were created for both tests to assess their effectiveness in identifying MCI in PD and iRBD. RESULTS: In PD, a normality cutoff of 138 on the DRS-2 yielded the best balance between sensitivity (72%) and specificity (86%) with a correct classification of 80%. In iRBD, the optimal normality cutoff was 141 on the DRS-2, with a sensitivity of 90%, a specificity of 71% and a correct classification of 82%. No cutoff for the MMSE was found to have acceptable sensitivity or specificity. CONCLUSION: The DRS-2 has satisfactory validity to detect MCI in PD or iRBD. The MMSE proved to be invalid as a screening test for MCI in both populations.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: Martijn L T M Müller; Kirk A Frey; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Roger L Albin; Nicolaas I Bohnen Journal: Mov Disord Date: 2012-12-12 Impact factor: 10.338
Authors: Martijn L T M Müller; Roger L Albin; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen Journal: Brain Date: 2013-09-20 Impact factor: 13.501
Authors: Francesca V Lopez; Lauren E Kenney; Adrianna Ratajska; Charles E Jacobson; Dawn Bowers Journal: Clin Neuropsychol Date: 2021-11-15 Impact factor: 4.373
Authors: Connie Marras; Melissa J Armstrong; Christopher A Meaney; Susan Fox; Brandon Rothberg; William Reginold; David F Tang-Wai; David Gill; Paul J Eslinger; Cindy Zadikoff; Nancy Kennedy; Fred J Marshall; Mark Mapstone; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; Sarah Duff-Canning Journal: Mov Disord Date: 2013-03-20 Impact factor: 10.338
Authors: Ondrej Bezdicek; Tomas Nikolai; Jiri Michalec; Filip Růžička; Petra Havránková; Jan Roth; Robert Jech; Evžen Růžička Journal: Mov Disord Clin Pract Date: 2016-07-08